 chemotherapi radiat therapi anal carcinoma surviv late morbid studi surviv late morbid rate chemotherapi radiat therapi regimen patient carcinoma anal canal patient radiat therapi cgi anteroposterior-posteroanterior ap-pa field chemotherapi mitomycin patient primari tumor complet respons rate surviv rate signific differ surviv rate tumor stage patient local recurr primari surgeri complet respons rate surviv rate fifteen percent patient late treatment-rel symptom anal incontin intestin obstruct chronic pelvic pain current treatment regimen effect consider risk complic surviv rate independ tumor stage locoregion treatment extens small tumor advanc tumor strategi late side effect patient small tumor surviv rate